All News

Phase 3 trial results for dupilumab (Dupixent) demonstrate improvement in skin clearing, itch, and certain quality of life measurements for adolescents with atopic dermatitis.

The phase 3 PARADIGMS clinical trial is the first-ever study designed for children and adolescents aged 10 to 17 years old with relapsing forms of multiple sclerosis.

Top news of the day from across the health care landscape.

A global phase 3a trial successfully demonstrated greater reductions in HbA1c and body weight with a oral semaglutide drug treatment than with dulaglutide, as well as a a comparable number of adverse events in 458 Japanese adults with type 2 diabetes between these medications.

Top news of the day from across the health care landscape.

Patients with multiple sclerosis incur higher costs and experience lower health-related quality of life as their disability increases

Pharmacy gag clauses forbid pharmacists from proactively telling consumers if their prescription would cost less if they paid for it out-of-pocket rather than using their insurance plan.

Implementation of universal health care is part of the Sustainable Development Goals (SDGs), which are new targets signed by 193 United Nations member states to improve health and development by 2030.

The American Hospital Association and individual hospitals have initiated new principles for ensuring good stewardship of the 340B drug program.

Top news of the day from across the health care landscape

According to evidence presented at trial, from approximately December 2011 to August 2015, Ramirez, Shepherd and Nwoko conspired and schemed to defraud Medicare out of payments for medical services.

Deaths due to poor-quality health care represent a substantial challenge for universal coverage in low- and middle-income countries.

Top news of the day from across the health care landscape

Sequential administration of HER2+ therapy and chemotherapy did not affect survival outcomes in patients with breast cancer.

Study establishes real-world efficacy, tolerability, and safety profile of sofosbuvir-based regimens in patients with chronic hepatitis C who have compensated liver cirrhosis.

The Patient Right to Know Drug Prices Act would prohibit insurers and prescription benefit managers from using gag clauses by health insurers and pharmacy benefit managers.

Almirall has received European Commission approval for its plaque psoriasis treatment tildrakizumab (Ilumetri).

The National Comprehensive Cancer Network updated its Clinical Practice Guidelines for kidney cancer to include new recommendations for cabozantinib tablets.

Tildrakizumab (Ilumetri) received approval by the European Commission for the treatment of moderate-to-severe chronic plaque psoriasis.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

When used in combination with an anti-PD-L1 therapy, a novel vaccine plus Diprovocim increased survival in mice with melanoma.

Study shows that it’s cost-effective to use the livers of HCV-positive patients even with the cost of direct-acting antiviral drugs to cure the virus.

As medication experts, pharmacists are integral to team-based care, providing the requisite knowledge for medication therapy management, as well as initiating, modifying and monitoring drug therapy to benefit patient care.

Researchers have identified a potential point of intervention that could prevent the progression of liver damage to cancer.

The vaginal inserts can reduce symptoms such as hot flashes and mood swings.

Officials with the FDA have approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

Top news of the day from across the health care landscape.

Study identifies receptor as potential target for reversing liver damage and preventing progression to cancer.